GALT · Galectin Therapeutics Inc
$3.44
-0.09 (-2.55%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$346.92M
Shares
100.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.44
Open$3.50
Day$3.20–3.55
52W close$2.08–6.51
Avg vol 30d497K
Short int8.7M · 8.6% float · 23.6d
Short vol58%
Last earningsAug 14, 2025
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−3%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
31%
mid-range
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+14%
trailing
YTD return
−17%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.62% of float · ▲ +2.4% MoM · 23.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
+37%
Y/Y
Free cash flow
$-23.9M
Balance sheet
$17.7M
net cash
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
9.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−3%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.62% of float · ▲ +2.4% MoM · 23.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 31%
Range high $7
vs 200-day avg -3%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GALT
this stock
Galectin Therapeutics Inc
|
$346.92M | -17.3% | — | — | 8.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GALT | -0.3% | -17.7% | +13.5% | +15.8% | -17.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.7% | -22.2% | -0.2% | +11.9% | -31.2% |
Key facts
CIK
1133416
CUSIP
363225202
13F (30d)
99 filings
97 filers
Visit website
Investor relations